Selective improvement in seattle heart failure model risk stratification using iodine-123 meta-iodobenzylguanidine imaging

Journal of Nuclear Cardiology

Volumn 19, Issue 5, 2012, Pages 1007-1016

  Ketchum, Eric S ^a   Jacobson, Arnold F ^b   Caldwell, James H ^a   Senior, Roxy ^c   Cerqueira, Manuel D ^d   Thomas, Gregory S ^e   Agostini, Denis ^f   Narula, Jagat ^g   Levy, Wayne C ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b GE HEALTHCARE   (United States)

^c NORTHWICK PARK HOSPITAL   (United Kingdom)

^d LERNER RESEARCH INSTITUTE   (United States)

^e LONG BEACH MEMORIAL MEDICAL CENTER   (United States)

^f CHU CÔTE DE NACRE   (France)

^g MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiac I 123 metaiodobenzylguanidine imaging; Heart failure; Prognosis; Seattle Heart Failure Model; Statistical modeling

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CARDIAC IMAGING; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR PARAMETERS; CARDIOVASCULAR RISK; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; ELECTROCARDIOGRAPHY; FEMALE; HEART TO MEDIASTINUM RATIO; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; SEATTLE HEART FAILURE MODEL; STATISTICAL MODEL; SURVIVAL PREDICTION; SURVIVAL RATE;

3-IODOBENZYLGUANIDINE; AGED; AGED, 80 AND OVER; AREA UNDER CURVE; FEMALE; HEART FAILURE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; RADIOPHARMACEUTICALS; RISK;

EID: 84868128380     PISSN: 10713581     EISSN: 15326551     Source Type: Journal    
DOI: 10.1007/s12350-012-9603-0     Document Type: Article

References (43)

1. Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, et al. Heart disease and stroke statistics-2012 update: A report from the American Heart Association. Circulation 2012;125:e2-220.
2. Levy WC, Mozaffarian D, Linker DT, Sutradhar SC, Anker SD, Cropp AB, et al. The Seattle Heart Failure Model: Prediction of survival in heart failure. Circulation 2006;113:1424-33.
3. May HT, Horne BD, LevyWC, Kfoury AG, Rasmusson KD, Linker DT, et al. Validation of the Seattle Heart Failure Model in a community-based heart failure population and enhancement by adding Btype natriuretic peptide. Am J Cardiol 2007;100:697-700.
4. Kalogeropoulos AP, Georgiopoulou VV, Giamouzis G, Smith AL, Agha SA, Waheed S, et al. Utility of the Seattle Heart Failure Model in patients with advanced heart failure. J Am Coll Cardiol 2009;53:334-42.
5. Ketchum ES, Moorman AJ, Fishbein DP, Mokadam NA, Verrier ED, Aldea GS, et al. Predictive value of the Seattle Heart Failure Model in patients undergoing left ventricular assist device placement. J Heart Lung Transplant 2010;29:1021-5.
6. Mozaffarian D, Anker SD, Anand I, Linker DT, Sullivan MD, Cleland JG, et al. Prediction of mode of death in heart failure: The Seattle Heart Failure Model. Circulation 2007;116:392-8.
7. Levy WC, Lee KL, Hellkamp AS, Poole JE, Mozaffarian D, Linker DT, et al. Maximizing survival benefit with primary prevention implantable cardioverter-defibrillator therapy in a heart failure population. Circulation 2009;120:835-42.
8. Ky B, French B, McCloskey K, Rame JE, McIntosh E, Shahi P, et al. High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure. Circ Heart Fail 2011;4:180-7.
9. Bristow MR, Ginsburg R, Minobe W, Cubicciotti RS, Sageman WS, Lurie K, et al. Decreased catecholamine sensitivity and betaadrenergic-receptor density in failing human hearts. N Engl J Med 1982;307:205-11.
10. Francis GS. Neurohumoral mechanisms involved in congestive heart failure. Am J Cardiol 1985;55:A15-21.
11. Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984;311:819-23.
12. Hasking GJ, Esler MD, Jennings GL, Burton D, Johns JA, Korner PI. Norepinephrine spillover to plasma in patients with congestive heart failure: Evidence of increased overall and cardiorenal sympathetic nervous activity. Circulation 1986;73:615-21.
13. Latini R, Masson S, Anand I, Salio M, Hester A, Judd D, et al. The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT. Eur Heart J 2004;25:292-9.
14. Lorvidhaya P, Addo K, Chodosh A, Iyer V, Lum J, Buxton AE. Sudden cardiac death risk stratification in patients with heart failure. Heart Fail Clin 2011;7:157-74. vii.
15. Kline RC, Swanson DP, Wieland DM, Thrall JH, Gross MD, Pitt B, et al. Myocardial imaging in man with I-123 meta-iodobenzylguanidine. J Nucl Med 1981;22:129-32.
16. Wieland DM, Brown LE, Rogers WL, Worthington KC, Wu JL, Clinthorne NH, et al. Myocardial imaging with a radioiodinated norepinephrine storage analog. J Nucl Med 1981;22:22-31.
17. Verberne HJ, Brewster LM, Somsen GA, van Eck-Smit BL. Prognostic value of myocardial 123I-metaiodobenzylguanidine (MIBG) parameters in patients with heart failure: A systematic review. Eur Heart J 2008;29:1147-59.
18. Momose M, Okayama D, Nagamatsu H, Kondo C, Hagiwara N, Sakai S. Long-term prognostic stratification by a combination of (123)I-metaiodobenzylguanidine scintigraphy and ejection fraction in dilated cardiomyopathy. Ann Nucl Med 2011;25:419-24.
19. Kuramoto Y, Yamada T, Tamaki S, Okuyama Y, Morita T, Furukawa Y. Usefulness of cardiac iodine-123 meta-iodobenzylguanidine imaging to improve prognostic power of Seattle Heart Failure Model in patients with chronic heart failure. Am J Cardiol 2011;107:1185-90.
20. Jacobson AF, Senior R, Cerqueira MD, Wong ND, Thomas GS, Lopez VA, et al. Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) study. J Am Coll Cardiol 2010;55:2212-21.
21. Jacobson AF, Lombard J, Banerjee G, Camici PG. 123I-mIBG scintigraphy to predict risk for adverse cardiac outcomes in heart failure patients: Design of two prospective multicenter international trials. J Nucl Cardiol 2009;16:113-21.
22. Lemeshow S, Hosmer DW Jr. A review of goodness of fit statistics for use in the development of logistic regression models. Am J Epidemiol 1982;115:92-106.
23. van Houwelingen HC. Validation, calibration, revision and combination of prognostic survival models. Stat Med 2000;19:3401-15.
24. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond. Stat Med 2008;27:157-72. (discussion 207-212).
25. Steyerberg EW, Vickers AJ, Cook NR, Gerds T, Gonen M, Obuchowski N, et al. Assessing the performance of prediction models: A framework for traditional and novel measures. Epidemiology 2010;21:128-38.
26. Cook NR. Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation 2007;115:928-35.
27. Bonow RO, Mann DL, Zipes DP, Libby P. Braunwald's heart disease: A textbook of cardiovascular medicine. Philadelphia: Elsevier; 2011.
28. Wang TJ, Gona P, Larson MG, Tofler GH, Levy D, Newton-Cheh C, et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med 2006;355:2631-9.
29. Levy WC, Aaronson KD, Dardas TF, Williams P, Haythe J, Mancini D. Prognostic impact of the addition of peak oxygen consumption to the Seattle Heart Failure Model in a transplant referral population. J Heart Lung Transplant 2012;31:817-24.
30. Ky B, French B, McCloskey K, Rame JE, McIntosh E, Shahi P, et al. High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure. Circ Heart Fail 2011;4:180-7.
31. Budoff MJ, Shaw LJ, Liu ST, Weinstein SR, Mosler TP, Tseng PH, et al. Long-term prognosis associated with coronary calcification: Observations from a registry of 25,253 patients. J Am Coll Cardiol 2007;49:1860-70.
32. Kasama S, Toyama T, Sumino H, Kumakura H, Takayama Y, Minami K, et al. Prognostic value of cardiac sympathetic nerve activity evaluated by [123I]m-iodobenzylguanidine imaging in patients with ST-segment elevation myocardial infarction. Heart 2011;97:20-6.
33. Akutsu Y, Kaneko K, Kodama Y, Li HL, Suyama J, Shinozuka A, et al. Iodine-123 mIBG imaging for predicting the development of atrial fibrillation. JACC Cardiovasc Imaging 2011;4:78-86.
34. Horiguchi Y, Morita Y, Tsurikisawa N, Akiyama K. 123I-MIBG imaging detects cardiac involvement and predicts cardiac events in Churg-Strauss syndrome. Eur J Nucl Med Mol Imaging 2011; 38:221-9.
35. Mancini D, Lietz K. Selection of cardiac transplantation candidates in 2010. Circulation 2010;122:173-83.
36. Strueber M, O'Driscoll G, Jansz P, Khaghani A, Levy WC, Wieselthaler GM. Multicenter evaluation of an intrapericardial left ventricular assist system. J Am Coll Cardiol 2011;57:1375-82.
37. Pamboukian SV, Tallaj JA, Brown RN, Nielsen T, George JF, Kirklin JK, et al. Comparison of observed survival after ventricular assist device placement versus predicted survival without assist device using the Seattle Heart Failure Model. ASAIO J 2012; 58:93-7.
38. Meyns BP, Simon A, Klotz S, Wittwer T, Schlensak C, Rega F, et al. Clinical benefits of partial circulatory support in New York Heart Association Class IIIB and Early Class IV patients. Eur J Cardiothorac Surg 2010;58:S173-8.
39. Klotz S, Meyns B, Simon A, Wittwer T, Rahmanian P, Schlensak C, et al. Partial mechanical long-term support with the CircuLite Synergy pump as bridge-to-transplant in congestive heart failure. Thorac Cardiovasc Surg 2010;58:S173-8.
40. Goldenberg I, Vyas AK, Hall WJ, Moss AJ, Wang H, He H, et al. Risk stratification for primary implantation of a cardioverterdefibrillator in patients with ischemic left ventricular dysfunction. J Am Coll Cardiol 2008;51:288-96.
41. Frankenstein L, Zugck C, Nelles M, Schellberg D, Remppis A, Katus H. Primary ICD-therapy in patients with advanced heart failure: Selection strategies and future trials. Clin Res Cardiol 2008;97:594-600.
42. Bax JJ, Kraft O, Buxton AE, Fjeld JG, Parizek P, Agostini D, et al. 123 I-mIBG scintigraphy to predict inducibility of ventricular arrhythmias on cardiac electrophysiology testing: A prospective multicenter pilot study. Circ Cardiovasc Imaging 2008;1:131-40.
43. Boogers MJ, Borleffs CJ, Henneman MM, van Bommel RJ, van Ramshorst J, Boersma E, et al. Cardiac sympathetic denervation assessed with 123-iodine metaiodobenzylguanidine imaging predicts ventricular arrhythmias in implantable cardioverterdefibrillator patients. J Am Coll Cardiol 2010;55:2769-77.